Levitra 10 mg With 1 Tablets - Vardenafil Trihydrate

LEVITRA (20 mg) did not potentiate the hypotensive effects of alcohol during the 4-hour observation period in healthy volunteers when administered with alcohol (0.5 g/kg body weight).

Customer reviews

Visual disturbances including vision loss (temporary or permanent), such as visual field defect, retinal vein occlusion, and reduced visual acuity, have also been reported rarely in post-marketing experience. It is not possible to determine whether these events are related directly to the use of LEVITRA. Seizure, seizure recurrence and transient global amnesia have been reported post-marketing in temporal association with LEVITRA. Cases of sudden decrease or loss of hearing have been reported post-marketing in temporal association with the use of PDE5 inhibitors, including LEVITRA. OVERDOSAGE The maximum dose of LEVITRA for which human data are available is a single 120 mg dose administered to eight healthy male volunteers.

RedBox Rx Reviews

The majority of these subjects experienced reversible back pain/myalgia and/or “abnormal vision.”In cases of overdose, standard supportive measures should be taken as required. Renal dialysis is not expected to accelerate clearance because vardenafil is highly bound to plasma proteins and is not significantly eliminated in the urine. The maximum dose of LEVITRA for which human data are available is a single 120 mg dose administered to eight healthy male volunteers. The majority of these subjects experienced reversible back pain/myalgia and/or “abnormal vision.” In cases of overdose, standard supportive measures should be taken as required. DOSAGE AND ADMINISTRATION For most patients, the recommended starting dose of LEVITRA is 10 vardenafil levitra mg, taken orally approximately 60 minutes before sexual activity.

Provider: Rx Outreach Medications

The dose may be increased to a maximum recommended dose of 20 mg or decreased to 5 mg based on efficacy and side effects. The maximum recommended dosing frequency is once per day. LEVITRA can be taken with or without food. Sexual stimulation is required for a response to treatment.Geriatrics: A starting dose of 5 mg LEVITRA should be considered in patients ≥65 years of age (see CLINICAL PHARMACOLOGY, Pharmacokinetics in Special Populations and PRECAUTIONS).Hepatic Impairment: For patients with mild hepatic impairment (Child-Pugh A), no dose adjustment of LEVITRA is required. Vardenafil clearance is reduced in patients with moderate hepatic impairment (Child-Pugh B), and a starting dose of 5 mg LEVITRA is recommended. Aspirin: LEVITRA (10 mg and 20 mg) did not potentiate the increase in bleeding time caused by aspirin (two 81 mg tablets). Other interactions: LEVITRA had no effect on the pharmacodynamics of glyburide (glucose and insulin concentrations) and warfarin (prothrombin time or other pharmacodynamic parameters). Vardenafil was not carcinogenic in rats and mice when administered daily for 24 months. In a corresponding 1-month rat toxicity study, this dose produced an AUC value for unbound vardenafil 200 fold greater than AUC in humans at the MRHD of 20 mg. There was no effect on sperm motility or morphology after single 20 mg oral doses of vardenafil in healthy volunteers. LEVITRA is not indicated for use in women, newborns, or children. It is not known if vardenafil is excreted in human breast milk. No evidence of specific potential for teratogenicity, embryotoxicity or fetotoxicity was observed in rats and rabbits that received vardenafil at up to 18 mg/kg/day during organogenesis. There are no adequate and well-controlled trials of vardenafil in pregnant women. Elderly males age 65 years and older have higher vardenafil plasma concentrations than younger males (18 – 45 years), mean Cmax and AUC were 34% and 52% higher, respectively (see CLINICAL PHARMACOLOGY,Pharmacokinetics in Special Populations, and DOSAGE AND ADMINISTRATION). ADVERSE REACTIONS LEVITRA was administered to over 4430 men (mean age 56, range 18-89 years; 81% White, 6% Black, 2% Asian, 2% Hispanic and 9% Other) during controlled and uncontrolled clinical trials worldwide.

Over 2200 patients were treated for 6 months or longer, and 880 patients were treated for at least 1 year.In placebo-controlled clinical trials, the discontinuation rate due to adverse events was 3.4% for LEVITRA compared to 1.1% for placebo.When LEVITRA was taken as recommended in placebo-controlled clinical trials, the following adverse events were reported (see Table 5).Back pain was reported in 2.0% of patients treated with LEVITRA and 1.7% of patients on placebo.Placebo-controlled trials suggested a dose effect in the incidence of some adverse events (headache, flushing, dyspepsia, nausea, rhinitis) over the 5 mg, 10 mg, and 20 mg doses of LEVITRA. The following section identifies additional, less frequent events (<2%) reported during the clinical development of LEVITRA. Excluded from this list are those events that are infrequent and minor, those events that may be commonly observed in the absence of drug therapy, and those events that are not reasonably associated with the drug.BODY AS A WHOLE: anaphylactic reaction (including laryngeal edema),asthenia, face edema, painAUDITORY: sudden decrease or loss of hearing, tinnitusCARDIOVASCULAR: angina pectoris, chest pain, hypertension,hypotension, myocardial ischemia, myocardial infarction, palpitation,postural hypotension, syncope, tachycardiaDIGESTIVE: abdominal pain, abnormal liver function tests, diarrhea, drymouth, dysphagia, esophagitis, gastritis, gastroesophageal reflux, GGTPincreased, vomitingMUSCULOSKELETAL: arthralgia, back pain, myalgia, neck painNERVOUS: hypertonia, hypesthesia, insomnia, paresthesia, somnolence,vertigoRESPIRATORY: dyspnea, epistaxis, pharyngitisSKIN AND APPENDAGES: photosensitivity reaction, pruritus, rash,sweatingOPHTHALMOLOGIC: abnormal vision, blurred vision, chromatopsia,changes in color vision, conjunctivitis (increased redness of the eye), dimvision, eye pain, glaucoma, photophobia, watery eyesUROGENITAL: abnormal ejaculation, priapism (including prolonged orpainful erections) LEVITRA was administered to over 4430 men (mean age 56, range 18-89 years; generic levitra pills canada 81% White, 6% Black, 2% Asian, 2% Hispanic and 9% Other) during controlled and uncontrolled clinical trials worldwide. Over 2200 patients were treated for 6 months or longer, and 880 patients were treated for at least 1 year. In placebo-controlled clinical trials, the discontinuation rate due to adverse events was 3.4% for LEVITRA compared to 1.1% for placebo. When LEVITRA was taken as recommended in placebo-controlled clinical trials, the following adverse events were reported (see Table 5). Back pain was reported in 2.0% of patients treated with LEVITRA and 1.7% of patients on placebo.

Click here for show notes

The maximum dose in patients with moderate hepatic impairment should not exceed 10 mg.

Can vardenafil treat all forms of ED?

Vardenafil compared to other PDE5 inhibitors

Placebo-controlled trials suggested a dose effect in the incidence of some adverse events (headache, flushing, dyspepsia, nausea, rhinitis) over the 5 mg, 10 mg, and 20 mg doses of LEVITRA. Excluded from this list are those events that are infrequent and minor, those events that may be commonly observed in the absence of drug therapy, and those events that are not reasonably associated with the drug. BODY AS A WHOLE: anaphylactic reaction (including laryngeal edema), AUDITORY: sudden decrease or loss of hearing, tinnitus DIGESTIVE: abdominal pain, abnormal liver function tests, diarrhea, dry MUSCULOSKELETAL: arthralgia, back pain, myalgia, neck pain SKIN AND APPENDAGES: photosensitivity reaction, pruritus, rash, UROGENITAL: abnormal ejaculation, priapism (including prolonged or POST-MARKETING EXPERIENCE OphthalmologicNon-arteritic anterior ischemic optic neuropathy (NAION), a cause of decreased vision including permanent loss of vision, has been reported rarely post-marketing in temporal association with the use of phosphodiesterase type 5 (PDE5) inhibitors, including LEVITRA. Most, but not all, of these patients had underlying anatomic or vascular risk factors for development of NAION, including but not necessarily limited to: low cup to disc ratio (“crowded disc”), age over 50, diabetes, hypertension, coronary artery disease, hyperlipidemia and smoking. It is not possible to determine whether these events are related directly to the use of PDE5 inhibitors, to the patient’s underlying vascular risk factors or anatomical defects, to a combination of these factors, or to other factors (see PRECAUTIONS, Information for Patients).Visual disturbances including vision loss (temporary or permanent), such as visual field defect, retinal vein occlusion, and reduced visual acuity, have also been reported rarely in post-marketing experience. It is not possible to determine whether these events are related directly to the use of LEVITRA.NeurologicSeizure, seizure recurrence and transient global amnesia have been reported post-marketing in temporal association with LEVITRA.OtologicCases of sudden decrease or loss of hearing have been reported post-marketing in temporal association with the use of PDE5 inhibitors, including LEVITRA. In some cases, medical conditions and other levitra price list factors were reported that may have also played a role in the otologic adverse events. In many cases, medical follow-up information was limited. It is not possible to determine whether these reported events are related directly to the use of LEVITRA, to the patient’s underlying risk factors for hearing loss, a combination of these factors, or to other factors (see PRECAUTIONS, Information for Patients).

• The price of Levitra 10mg can range from $20 to $50 per pill.
• Insurance rarely covers Levitra 10mg, making out-of-pocket costs important.
• Some pharmacies offer discounts or bulk deals on Levitra 10mg.
• Prices for Levitra 10mg vary depending on the country and retailer.
• Always ensure the authenticity of Levitra 10mg to avoid counterfeit drugs.

Non-arteritic anterior ischemic optic neuropathy (NAION), a cause of decreased vision including permanent loss of vision, has been reported rarely post-marketing in temporal association with the use of phosphodiesterase type 5 (PDE5) inhibitors, including LEVITRA. It is not possible to determine whether these events are related directly to the use of PDE5 inhibitors, to the patient’s underlying vascular risk factors or anatomical defects, to a combination of these factors, or to other factors (see PRECAUTIONS, Information for Patients).

Visual disturbances including vision loss (temporary or permanent), such as visual field defect, retinal vein occlusion, and reduced visual acuity, have also been reported rarely in post-marketing experience. It is not possible to determine whether these events are related directly to the use of LEVITRA. Seizure, seizure recurrence and transient global amnesia have been reported post-marketing in temporal association with LEVITRA. Cases of sudden decrease or loss of hearing have been reported post-marketing in temporal association with the use of PDE5 inhibitors, including LEVITRA.

Information for Patients

LEVITRA (20 mg) did not potentiate the hypotensive effects of alcohol during the 4-hour observation period in healthy volunteers when administered with alcohol (0.5 g/kg body weight). Aspirin: LEVITRA (10 mg and 20 mg) did not potentiate the increase in bleeding time caused by aspirin (two 81 mg tablets). Other interactions: LEVITRA had no effect on the pharmacodynamics of glyburide (glucose and insulin concentrations) and warfarin (prothrombin time or other pharmacodynamic parameters). Vardenafil was not carcinogenic in rats and mice when administered daily for 24 months. In a corresponding 1-month rat toxicity study, this dose produced an AUC value for unbound vardenafil 200 fold greater than AUC in humans at the MRHD of 20 mg.

Medicines You Shouldn’t Take with Vardenafil:

There was no effect on sperm motility or morphology after single 20 mg oral doses of vardenafil in healthy volunteers. LEVITRA is not indicated for use in women, newborns, or children. It is not known if vardenafil is excreted in human breast milk. No evidence of specific potential for teratogenicity, embryotoxicity or fetotoxicity was observed in rats and rabbits that received vardenafil at up to 18 mg/kg/day during organogenesis. There are no adequate and well-controlled trials of vardenafil in pregnant women.

Pharmacokinetics in Special Populations

Elderly males age 65 years and older have higher vardenafil plasma concentrations than younger males (18 – 45 years), mean Cmax and AUC were 34% and 52% higher, respectively (see CLINICAL PHARMACOLOGY,Pharmacokinetics in Special Populations, and DOSAGE AND ADMINISTRATION). ADVERSE REACTIONS LEVITRA was administered to over 4430 men (mean age 56, range 18-89 years; 81% White, 6% Black, 2% Asian, 2% Hispanic and 9% Other) during controlled and uncontrolled clinical trials worldwide. Over 2200 patients were treated for 6 months or longer, and 880 patients were treated for at least 1 year.In placebo-controlled clinical trials, the discontinuation rate due to adverse events was 3.4% for LEVITRA compared to 1.1% for placebo.When LEVITRA was taken as recommended in placebo-controlled clinical trials, the following adverse events were reported (see Table 5).Back pain was reported in 2.0% of patients treated with LEVITRA and 1.7% of patients on placebo.Placebo-controlled trials suggested a dose effect in the incidence of some adverse events (headache, flushing, dyspepsia, nausea, rhinitis) over the 5 mg, 10 mg, and 20 mg doses of LEVITRA. The following section identifies additional, less frequent events (<2%) reported during the clinical development of LEVITRA. Excluded from this list are those events that are infrequent and minor, those events that may be commonly observed in the absence of drug therapy, and those events that are not reasonably associated with the drug.BODY AS A WHOLE: anaphylactic reaction (including laryngeal edema),asthenia, face edema, painAUDITORY: sudden decrease or loss of hearing, tinnitusCARDIOVASCULAR: angina pectoris, chest pain, hypertension,hypotension, myocardial ischemia, myocardial infarction, palpitation,postural hypotension, syncope, tachycardiaDIGESTIVE: abdominal pain, abnormal liver function tests, diarrhea, drymouth, dysphagia, esophagitis, gastritis, gastroesophageal reflux, GGTPincreased, vomitingMUSCULOSKELETAL: arthralgia, back pain, myalgia, neck painNERVOUS: hypertonia, hypesthesia, insomnia, paresthesia, somnolence,vertigoRESPIRATORY: dyspnea, epistaxis, pharyngitisSKIN AND APPENDAGES: photosensitivity reaction, pruritus, rash,sweatingOPHTHALMOLOGIC: abnormal vision, blurred vision, chromatopsia,changes in color vision, conjunctivitis (increased redness of the eye), dimvision, eye pain, glaucoma, photophobia, watery eyesUROGENITAL: abnormal ejaculation, priapism (including prolonged orpainful erections) LEVITRA was administered to over 4430 men (mean age 56, range 18-89 years; generic levitra pills canada 81% White, 6% Black, 2% Asian, 2% Hispanic and 9% Other) during controlled and uncontrolled clinical trials worldwide. OVERDOSAGE The maximum dose of LEVITRA for which human data are available is a single 120 mg dose administered to eight healthy male volunteers.

• Patients might experience side effects like headache or flushing from Levitra 10mg.
• Levitra 10mg may interact with certain medications, such as nitrates.
• Alcohol consumption can affect the efficacy and safety of Levitra 10mg.
• Always report any adverse reactions when taking Levitra 10mg to your doctor.
• Levitra 10mg should be used with caution in patients with cardiovascular issues.

The majority of these subjects experienced reversible back pain/myalgia and/or “abnormal vision.”In cases of overdose, standard supportive measures should be taken as required.

Renal dialysis is not expected to accelerate clearance because vardenafil is highly bound to plasma proteins and is not significantly eliminated in the urine. The maximum dose of LEVITRA for which human data are available is a single 120 mg dose administered to eight healthy male volunteers.

Brand for: Vardenafil

Over 2200 patients were treated for 6 months or longer, and 880 patients were treated for at least 1 year. In placebo-controlled clinical trials, the discontinuation rate due to adverse events was 3.4% for LEVITRA compared to 1.1% for placebo. When LEVITRA was taken as recommended in placebo-controlled clinical trials, the following adverse events were reported (see Table 5). Back pain was reported in 2.0% of patients treated with LEVITRA and 1.7% of patients on placebo. Placebo-controlled trials suggested a dose effect in the incidence of some adverse events (headache, flushing, dyspepsia, nausea, rhinitis) over the 5 mg, 10 mg, and 20 mg doses of LEVITRA.

Important Information

Excluded from this list are those events that are infrequent and minor, those events that may be commonly observed in the absence of drug therapy, and those events that are not reasonably associated with the drug. BODY AS A WHOLE: anaphylactic reaction (including laryngeal edema), AUDITORY: sudden decrease or loss of hearing, tinnitus DIGESTIVE: abdominal pain, abnormal liver function tests, diarrhea, dry MUSCULOSKELETAL: arthralgia, back pain, myalgia, neck pain SKIN AND APPENDAGES: photosensitivity reaction, pruritus, rash, UROGENITAL: abnormal ejaculation, priapism (including prolonged or POST-MARKETING EXPERIENCE OphthalmologicNon-arteritic anterior ischemic optic neuropathy (NAION), a cause of decreased vision including permanent loss of vision, has been reported rarely post-marketing in temporal association with the use of phosphodiesterase type 5 (PDE5) inhibitors, including LEVITRA. Most, but not all, of these patients had underlying anatomic or vascular risk factors for development of NAION, including but not necessarily limited to: low cup to disc ratio (“crowded disc”), age over 50, diabetes, hypertension, coronary artery disease, hyperlipidemia and smoking. It is not possible to determine whether these events are related directly to the use of PDE5 inhibitors, to the patient’s underlying vascular risk factors or anatomical defects, to a combination of these factors, or to other factors (see PRECAUTIONS, Information for Patients).Visual disturbances including vision loss (temporary or permanent), such as visual field defect, retinal vein occlusion, and reduced visual acuity, have also been reported rarely in post-marketing experience. It is not possible to determine whether these events are related directly to the use of LEVITRA.NeurologicSeizure, seizure recurrence and transient global amnesia have been reported post-marketing in temporal association with LEVITRA.OtologicCases of sudden decrease or loss of hearing have been reported post-marketing in temporal association with the use of PDE5 inhibitors, including LEVITRA.

What happens if I take too much Levitra?

In some cases, medical conditions and other levitra price list factors were reported that may have also played a role in the otologic adverse events. In many cases, medical follow-up information was limited. It is not possible to determine whether these reported events are related directly to the use of LEVITRA, to the patient’s underlying risk factors for hearing loss, a combination of these factors, or to other factors (see PRECAUTIONS, Information for Patients). Non-arteritic anterior ischemic optic neuropathy (NAION), a cause of decreased vision including permanent loss of vision, has been reported rarely post-marketing in temporal association with the use of phosphodiesterase type 5 (PDE5) inhibitors, including LEVITRA. It is not possible to determine whether these events are related directly to the use of PDE5 inhibitors, to the patient’s underlying vascular risk factors or anatomical defects, to a combination of these factors, or to other factors (see PRECAUTIONS, Information for Patients). The majority of these subjects experienced reversible back pain/myalgia and/or “abnormal vision.” In cases of overdose, standard supportive measures should be taken as required. DOSAGE AND ADMINISTRATION For most patients, the recommended starting dose of LEVITRA is 10 vardenafil levitra mg, taken orally approximately 60 minutes before sexual activity. The dose may be increased to a maximum recommended dose of 20 mg or decreased to 5 mg based on efficacy and side effects.

The maximum recommended dosing frequency is once per day. LEVITRA can be taken with or without food. Sexual stimulation is required for a response to treatment.Geriatrics: A starting dose of 5 mg LEVITRA should be considered in patients ≥65 years of age (see CLINICAL PHARMACOLOGY, Pharmacokinetics in Special Populations and PRECAUTIONS).Hepatic Impairment: For patients with mild hepatic impairment (Child-Pugh A), no dose adjustment of LEVITRA is required. Vardenafil clearance is reduced in patients with moderate hepatic impairment (Child-Pugh B), and a starting dose of 5 mg LEVITRA is recommended. The maximum dose in patients with moderate hepatic impairment should not exceed 10 mg.